Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Gilead Sciences provides grants for innovative projects that make a significant impact within their core therapeutic areas: HIV, liver diseases (HCV, HBV, HDV), oncology (hematology, solid tumors), and inflammatory and respiratory diseases. Their grant program prioritizes applications demonstrating a strong commitment to delivering specific services supported by the grant. It encompasses funding for:
Patient Community Support: These projects aim to raise awareness about disease prevention, care options, and reduce disparities in care, especially among at-risk populations. Funding examples include educational events, resources for disease education, and testing and screening initiatives.
Medical & Scientific Support: Gilead funds continuing medical education and scientific research to enhance healthcare professionals' knowledge and skills. Projects may include accredited CME programs, scientific conferences, and educational symposia.
Gilead is also committed to addressing healthcare needs in Latin America and the Caribbean, focusing on improving healthcare access, reducing disparities, and supporting education and community projects, especially those targeting HIV and liver diseases. While priority is given to HIV- and liver disease-related projects, Gilead is open to proposals in other areas that align with their eligibility restrictions. There are no fixed minimum or maximum funding amounts; applicants are encouraged to request funding that matches their programmatic needs.
non laboris consectetur aliqua laboris velit officia amet laborum quis aute aute ut sit sunt eiusmod aute irure laborum labore occaecat et cillum nisi excepteur labore ad